Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy
Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer...
Gespeichert in:
| Veröffentlicht in: | Advanced healthcare materials 2021-06, Vol.10 (11), p.e2002139-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | e2002139 |
| container_title | Advanced healthcare materials |
| container_volume | 10 |
| creator | Ye, Qian‐Ni Wang, Yue Shen, Song Xu, Cong‐Fei Wang, Jun |
| description | Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off‐target cytotoxicity. In recent years, an increasing number of biomaterials‐based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody‐based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state‐of‐the‐art in biomaterials‐based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials‐based delivery of antitumor antibodies are also discussed.
This review summarizes the current state‐of‐the‐art biomaterials‐based antibody delivery systems and their applications in cancer treatment from two main aspects: local delivery and systemic delivery, highlighting how the delivery systems can augment the therapeutic efficacy of antibody drugs. Even so, the translation of biomaterials‐based antibody delivery systems from lab to clinical application still requires further research and consideration. |
| doi_str_mv | 10.1002/adhm.202002139 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2515072222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2515072222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4399-c199d6c7b10285a90aabd095efb0270eb8ebd0a5b3aef5e2b69007e4e6e1edfc3</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0Eoqh0ZUSRWFhSznbz4bEfQEFFLGW2nOSiuspHsRNQNn4Cv5FfgquWIrFww_lOevzo9BJyQWFIAdiNylblkAFzM-XiiJwxKpjPwkAcH-YR9MjA2jW4CgMaxvSU9DiPIwh5dEYeJ7ouVYNGq8J-fXxOlMXMm2Gh39B0Xp17yxUatcG20ak3rhqd1JlG6-W18aaqStHsie6cnOROgoP92ycvd7fL6dxfPN8_TMcLPx1xIfyUCpGFaZRQYHGgBCiVZCACzBNgEWASo9tVkHCFeYAsCQVAhCMMkWKWp7xPrnfejalfW7SNLLVNsShUhXVrJQtoABFz5dCrP-i6bk3lrnMUF8C5644a7qjU1NYazOXG6FKZTlKQ26DlNmh5CNp9uNxr26TE7ID_xOoAsQPedYHdPzo5ns2ffuXfJwGKWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539033539</pqid></control><display><type>article</type><title>Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy</title><source>Wiley Online Library All Journals</source><creator>Ye, Qian‐Ni ; Wang, Yue ; Shen, Song ; Xu, Cong‐Fei ; Wang, Jun</creator><creatorcontrib>Ye, Qian‐Ni ; Wang, Yue ; Shen, Song ; Xu, Cong‐Fei ; Wang, Jun</creatorcontrib><description>Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off‐target cytotoxicity. In recent years, an increasing number of biomaterials‐based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody‐based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state‐of‐the‐art in biomaterials‐based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials‐based delivery of antitumor antibodies are also discussed.
This review summarizes the current state‐of‐the‐art biomaterials‐based antibody delivery systems and their applications in cancer treatment from two main aspects: local delivery and systemic delivery, highlighting how the delivery systems can augment the therapeutic efficacy of antibody drugs. Even so, the translation of biomaterials‐based antibody delivery systems from lab to clinical application still requires further research and consideration.</description><identifier>ISSN: 2192-2640</identifier><identifier>EISSN: 2192-2659</identifier><identifier>DOI: 10.1002/adhm.202002139</identifier><identifier>PMID: 33870637</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; antibody drugs ; Anticancer properties ; Antitumor activity ; Biocompatibility ; Biomaterials ; Biomedical materials ; Cancer ; cancer immunotherapy ; Cancer therapies ; cancer treatment ; Cytotoxicity ; delivery system ; Drugs ; Immobilization ; Monoclonal antibodies ; Therapy ; Toxicity ; Tumors</subject><ispartof>Advanced healthcare materials, 2021-06, Vol.10 (11), p.e2002139-n/a</ispartof><rights>2021 Wiley‐VCH GmbH</rights><rights>2021 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4399-c199d6c7b10285a90aabd095efb0270eb8ebd0a5b3aef5e2b69007e4e6e1edfc3</citedby><cites>FETCH-LOGICAL-c4399-c199d6c7b10285a90aabd095efb0270eb8ebd0a5b3aef5e2b69007e4e6e1edfc3</cites><orcidid>0000-0001-9957-9208 ; 0000-0002-1347-8324</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadhm.202002139$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadhm.202002139$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33870637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Qian‐Ni</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Shen, Song</creatorcontrib><creatorcontrib>Xu, Cong‐Fei</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><title>Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy</title><title>Advanced healthcare materials</title><addtitle>Adv Healthc Mater</addtitle><description>Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off‐target cytotoxicity. In recent years, an increasing number of biomaterials‐based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody‐based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state‐of‐the‐art in biomaterials‐based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials‐based delivery of antitumor antibodies are also discussed.
This review summarizes the current state‐of‐the‐art biomaterials‐based antibody delivery systems and their applications in cancer treatment from two main aspects: local delivery and systemic delivery, highlighting how the delivery systems can augment the therapeutic efficacy of antibody drugs. Even so, the translation of biomaterials‐based antibody delivery systems from lab to clinical application still requires further research and consideration.</description><subject>Antibodies</subject><subject>antibody drugs</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Biocompatibility</subject><subject>Biomaterials</subject><subject>Biomedical materials</subject><subject>Cancer</subject><subject>cancer immunotherapy</subject><subject>Cancer therapies</subject><subject>cancer treatment</subject><subject>Cytotoxicity</subject><subject>delivery system</subject><subject>Drugs</subject><subject>Immobilization</subject><subject>Monoclonal antibodies</subject><subject>Therapy</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2192-2640</issn><issn>2192-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAQhi0Eoqh0ZUSRWFhSznbz4bEfQEFFLGW2nOSiuspHsRNQNn4Cv5FfgquWIrFww_lOevzo9BJyQWFIAdiNylblkAFzM-XiiJwxKpjPwkAcH-YR9MjA2jW4CgMaxvSU9DiPIwh5dEYeJ7ouVYNGq8J-fXxOlMXMm2Gh39B0Xp17yxUatcG20ak3rhqd1JlG6-W18aaqStHsie6cnOROgoP92ycvd7fL6dxfPN8_TMcLPx1xIfyUCpGFaZRQYHGgBCiVZCACzBNgEWASo9tVkHCFeYAsCQVAhCMMkWKWp7xPrnfejalfW7SNLLVNsShUhXVrJQtoABFz5dCrP-i6bk3lrnMUF8C5644a7qjU1NYazOXG6FKZTlKQ26DlNmh5CNp9uNxr26TE7ID_xOoAsQPedYHdPzo5ns2ffuXfJwGKWw</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Ye, Qian‐Ni</creator><creator>Wang, Yue</creator><creator>Shen, Song</creator><creator>Xu, Cong‐Fei</creator><creator>Wang, Jun</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QP</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7T5</scope><scope>7TA</scope><scope>7TB</scope><scope>7TM</scope><scope>7TO</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9957-9208</orcidid><orcidid>https://orcid.org/0000-0002-1347-8324</orcidid></search><sort><creationdate>20210601</creationdate><title>Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy</title><author>Ye, Qian‐Ni ; Wang, Yue ; Shen, Song ; Xu, Cong‐Fei ; Wang, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4399-c199d6c7b10285a90aabd095efb0270eb8ebd0a5b3aef5e2b69007e4e6e1edfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>antibody drugs</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Biocompatibility</topic><topic>Biomaterials</topic><topic>Biomedical materials</topic><topic>Cancer</topic><topic>cancer immunotherapy</topic><topic>Cancer therapies</topic><topic>cancer treatment</topic><topic>Cytotoxicity</topic><topic>delivery system</topic><topic>Drugs</topic><topic>Immobilization</topic><topic>Monoclonal antibodies</topic><topic>Therapy</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Qian‐Ni</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Shen, Song</creatorcontrib><creatorcontrib>Xu, Cong‐Fei</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Immunology Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced healthcare materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Qian‐Ni</au><au>Wang, Yue</au><au>Shen, Song</au><au>Xu, Cong‐Fei</au><au>Wang, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy</atitle><jtitle>Advanced healthcare materials</jtitle><addtitle>Adv Healthc Mater</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>10</volume><issue>11</issue><spage>e2002139</spage><epage>n/a</epage><pages>e2002139-n/a</pages><issn>2192-2640</issn><eissn>2192-2659</eissn><abstract>Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off‐target cytotoxicity. In recent years, an increasing number of biomaterials‐based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody‐based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state‐of‐the‐art in biomaterials‐based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials‐based delivery of antitumor antibodies are also discussed.
This review summarizes the current state‐of‐the‐art biomaterials‐based antibody delivery systems and their applications in cancer treatment from two main aspects: local delivery and systemic delivery, highlighting how the delivery systems can augment the therapeutic efficacy of antibody drugs. Even so, the translation of biomaterials‐based antibody delivery systems from lab to clinical application still requires further research and consideration.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33870637</pmid><doi>10.1002/adhm.202002139</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0001-9957-9208</orcidid><orcidid>https://orcid.org/0000-0002-1347-8324</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-2640 |
| ispartof | Advanced healthcare materials, 2021-06, Vol.10 (11), p.e2002139-n/a |
| issn | 2192-2640 2192-2659 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2515072222 |
| source | Wiley Online Library All Journals |
| subjects | Antibodies antibody drugs Anticancer properties Antitumor activity Biocompatibility Biomaterials Biomedical materials Cancer cancer immunotherapy Cancer therapies cancer treatment Cytotoxicity delivery system Drugs Immobilization Monoclonal antibodies Therapy Toxicity Tumors |
| title | Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A41%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomaterials%E2%80%90Based%20Delivery%20of%20Therapeutic%20Antibodies%20for%20Cancer%20Therapy&rft.jtitle=Advanced%20healthcare%20materials&rft.au=Ye,%20Qian%E2%80%90Ni&rft.date=2021-06-01&rft.volume=10&rft.issue=11&rft.spage=e2002139&rft.epage=n/a&rft.pages=e2002139-n/a&rft.issn=2192-2640&rft.eissn=2192-2659&rft_id=info:doi/10.1002/adhm.202002139&rft_dat=%3Cproquest_cross%3E2515072222%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539033539&rft_id=info:pmid/33870637&rfr_iscdi=true |